Skip to main content

Sutter Martin P's Form 4 filing

Abiomed IncABMD · filed Nov 17, 2022

Accession no.
0001415889-22-011489
Filed
Nov 17, 2022
Trade date
Nov 15-16, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions. Open-market sales total $1.50M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Sutter Martin PCIK 0001017832Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2022Common Stock, $0.01 par valueSSaleDisposed−1,133$374.18F2−$423,945.94122,237Direct
Nov 15, 2022Common Stock, $0.01 par valueSSaleDisposed−867$374.92F3−$325,055.64121,370Direct
Nov 16, 2022Common Stock, $0.01 par valueSSaleDisposed−1,859$374.66F4−$696,492.94119,511Direct
Nov 16, 2022Common Stock, $0.01 par valueSSaleDisposed−141$375.56F5−$52,953.96119,370Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This price represents the sale price of the transactions on the reported date at $374.1828. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F3

This price represents the sale price of the transactions on the reported date at $374.9239. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F4

This price represents the sale price of the transactions on the reported date at $374.6617. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

F5

This price represents the sale price of the transactions on the reported date at $375.5611. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)